海外の治験の状況「前立腺癌」での検索結果
22件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A multinational study to evaluate the safety and effectiveness of enzalutamide in patients whose prostate cancer has not metastasized
- Patients With Nonmetastatic Castration Resistant Prostate Cancer br>MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Denmark, Finland, France, Germany, Greece, Hong Kong, Italy, Korea, Republic of, Malaysia, Netherlands, New Zealand, Poland, Russian Federation, Serbia, Singapore, Slovakia, Spain, Sweden, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
- 2013-07-10
Authorised
- An International Study to Evaluate the Safety and Effectiveness of MDV3100 in Patients with Prostate Cancer Where Their Cancer Has Progressed Despite Hormonal Therapy
- Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Russian Federation, Singapore, Slovakia, Spain, Sweden, United Kingdom, United States
- 2010-07-14
Authorised
- A study to provide access to continued treatment for subjects with prostate cancer who are currently participating in an enzalutamide clinical study
- metastatic castration-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Denmark, Finland, France, Georgia, Germany, Israel, Italy, Korea, Republic of, Lithuania, Moldova, Republic of, New Zealand, Poland, Russian Federation, Slovakia, South Africa, Spain, Sweden, United Kingdom, United States
- 2016-09-29
Authorised
- A study to provide access to continued treatment for subjects with prostate cancer who are currently participating in an enzalutamide clinical study
- metastatic castration-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Denmark, Finland, France, Georgia, Germany, Israel, Italy, Japan, Korea, Republic of, Lithuania, Moldova, Republic of, Netherlands, New Zealand, Russian Federation, Slovakia, South Africa, Spain, Sweden, Taiwan, United Kingdom, United States
- 2016-09-30
Authorised
- An exploratory study to assess the efficacy using imaging of oral enzalutamide in patients with therapy-resistant prostate cancer who have not been treated with androgen deprivation.
- Patients with Metastatic Prostate Cancer who have never been treated with Androgen Deprivation Therapy MedDRA version: 18.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- Austria, Belgium, Germany, Netherlands, Spain, Switzerland
- 2015-04-13
Authorised
- An exploratory study to assess the efficacy using imaging of oral Enzalutamide in patients with therapy-resistant prostate cancer who have not been treated with anti-androgens.
- Chemo-Naïve patients with Progressive Prostate Cancer who have failed Androgen Deprivation Therapy (CRPC patients) MedDRA version: 18.0 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- Austria, Belgium, Germany, Netherlands, Spain, Switzerland
- 2015-04-13
Authorised
- A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients
- Hormone-refractory prostate cancer MedDRA version: 9.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer
- Austria, Belgium, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Portugal, Spain, Sweden, United Kingdom
- 2007-11-20
Authorised
- Comparison of efficacy and safety of DCVAC/PCa (therapeutic prostate cancer immunotheraphy) against placebo in men with metastatic prostate cancer eligible for chemotherapy
- metastatic castrate-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, France, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, Serbia, Slovakia, Spain, Sweden, United Kingdom, United States
- 2013-04-04
Authorised
- A study in male patients with newly diagnosed prostate cancer to assess the accuracy of an imaging tracer at diagnosing prostate cancer, in comparison to standard prostate biopsy. In addition, the study will collect additional data on the tracers safety, look at the possible ability in the tracer detecting cancer spread to nearby bone and look at the tumour uptake of the tracer.
- Prostate cancer (PCA) with high risk of metastasis. MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
- Austria, Germany, Switzerland
- 2017-04-05
Authorised
- The aim of the study is to see if a new drug, enzalutamide, can improve outcomes for patients with metastatic prostate cancer compared with current treatment.This is a randomised controlled study trial which means that half the participants on the trial study will get enzalutamide and the other half will get current standard of care. All participants will receive active treatment for their cancer.
- Metastatic Prostate Cancer br>MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, France, Ireland, New Zealand, Poland, United Kingdom, United States
- 2014-11-21
